Figure 4. Candidate outcome variants at 1q22 are coincident with an ovarian super-enhancer that is predicted to target MEF2D.

The figure shows candidate outcome variants, H3K4Me1 modification in normal ovarian tissue and super-enhancers (ovarian super-enhancer is colored green and super-enhancers from other tissues blue) at the 1q22 ovarian outcome locus that are predicted to target MEF2D (Supplementary Table 3). Putative Regulatory Elements (PREs), and their coincident candidate variants, cloned into reporter gene constructs are highlighted in blue. The original lead variant associated with any chemotherapy OS, rs6674079, is shown with correlated candidate outcome variants (r² > 0.4) in black and the lead variant from the new OncoArray analysis with all chemotherapy OS, rs11264494, in blue (region cloned into reporter gene constructs highlighted in purple).